Why the study?
Does a left ventricular assist device and specific pharmacologic regimen improve sustained reversal of severe heart failure in selected patients with severe heart failure secondary to nonischemic cardiomyopathy?
Does a left ventricular assist device and specific pharmacologic regimen improve sustained reversal of severe heart failure in selected patients with severe heart failure secondary to nonischemic cardiomyopathy?
A combination of a left ventricular assist device and specific pharmacologic therapy can achieve sustained reversal of severe heart failure in selected patients with nonischemic cardiomyopathy.
May support LVAD plus pharmacotherapy for reversal in selected nonischemic HF; hypothesis-generating and requires randomized confirmation before practice change.
In this single-center study, we found that sustained reversal of severe heart failure secondary to nonischemic cardiomyopathy could be achieved in selected patients with the use of a left ventricular assist device and a specific pharmacologic regimen.
No takes yet. Share an insight, caveat, or question.
Birks et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: